Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing first- and best-in-class cellular immunotherapies for cancers and orphan inherited blood disorders.

The company is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. Our product candidates are differentiated by the inclusion of powerful molecular switches designed to eliminate, reduce or activate therapeutic cells, and thereby potentially provide greater efficacy and safety compared to the current generation of cell therapies. Our approach has yielded highly encouraging results to date from our lead BPX-501 program in the haploidentical transplant setting, and has been granted orphan drug designation from the U.S. FDA and the EMA. We have ongoing Phase 1 clinical trials with our BPX-601 GoCAR-T product candidate in the initial indication of non-resectable pancreatic cancer, and with our BPX-701 TCR product candidate in refractory or relapsed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Contact Bellicum Pharmaceuticals
832-384-1100
BMC Communications Brad Miles 646-513-3125 bmiles@bmccommunications.com
Visit Website